Related Experiment Video
Updated: Jun 28, 2025
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Targeting PRL phosphatases in hematological malignancies
Shiyu Xiao1, Hongxia Chen1,2, Yunpeng Bai3
1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Introduction:
Phosphatase of regenerating liver (PRL) family proteins, also known as protein tyrosine phosphatase 4A (PTP4A), have been implicated in many types of cancers. The PRL family of phosphatases consists of three members, PRL1, PRL2, and PRL3. PRLs have been shown to harbor oncogenic potentials and are highly expressed in a variety of cancers. Given their roles in cancer progression and metastasis, PRLs are potential targets for anticancer therapies. However, additional studies are needed to be performed to fully understand the roles of PRLs in blood cancers.
Areas Covered:
In this review, we will summarize recent studies of PRLs in normal and malignant hematopoiesis, the role of PRLs in regulating various signaling pathways, and the therapeutic potentials of targeting PRLs in hematological malignancies. We will also discuss how to improve current PRL inhibitors for cancer treatment.
Expert Opinion:
Although PRL inhibitors show promising therapeutic effects in preclinical studies of different types of cancers, moving PRL inhibitors from bench to bedside is still challenging. More potent and selective PRL inhibitors are needed to target PRLs in hematological malignancies and improve treatment outcomes.
Insights
Phosphatase of regenerating liver (PRL) proteins are key in many cancers. This review explores their role in blood cancers and discusses developing better PRL inhibitors for improved treatment outcomes.
Area of Science:
- Biochemistry
- Oncology
- Hematology
Background:
- Phosphatase of regenerating liver (PRL) proteins, also known as protein tyrosine phosphatase 4A (PTP4A), are implicated in various cancers.
- The PRL family (PRL1, PRL2, PRL3) exhibits oncogenic potential and is highly expressed in diverse malignancies.
- PRLs are crucial in cancer progression and metastasis, making them potential therapeutic targets.
Purpose of the Study:
- To review recent studies on PRLs in normal and malignant hematopoiesis.
- To elucidate the role of PRLs in regulating signaling pathways relevant to blood cancers.
- To discuss the therapeutic potential of targeting PRLs in hematological malignancies and improving existing inhibitors.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of signaling pathways regulated by PRLs.
- Evaluation of current and potential therapeutic strategies targeting PRLs.
Main Results:
- PRLs are involved in both normal and malignant hematopoiesis.
- PRLs regulate key signaling pathways implicated in blood cancer development.
- Preclinical studies show promise for PRL inhibitors in various cancers.
Conclusions:
- Further research is essential to fully understand PRL functions in blood cancers.
- Developing more potent and selective PRL inhibitors is critical for effective hematological malignancy treatment.
- Translating promising preclinical findings into clinical success remains a significant challenge.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...